10th Feb 2016 09:59
LONDON (Alliance News) - Medical research organisation Cyprotex PLC said Wednesday it has agreed a strategic partnering deal with Texas-based Cytocentrics Inc to expand its capabilities in the in-vitro ion channel screening market.
Under the agreement Cytocentrics will provide equipment, cell lines, expertise and training to allow Cyprotex to provide a panel of different ion channel assays from its Watertown site near Boston in the US.
The new facility, which is expected to be operational in the first half of 2016, is expected to contribute to the company's performance in the second half of the year.
Shares in Cyprotex were trading flat at 104.47 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L